Literature DB >> 20101232

ERalpha signaling through slug regulates E-cadherin and EMT.

Y Ye1, Y Xiao, W Wang, K Yearsley, J X Gao, B Shetuni, S H Barsky.   

Abstract

The ERalpha signaling pathway is one of the most important and most studied pathways in human breast cancer, yet numerous questions still exist such as how hormonally responsive cancers progress to a more aggressive and hormonally independent phenotype. We have noted that human breast cancers exhibit a strong direct correlation between ERalpha and E-cadherin expression by immunohistochemistry, suggesting that ERalpha signaling might regulate E-cadherin and implying that this regulation might influence epithelial-mesenchymal transition (EMT) and tumor progression. To investigate this hypothesis and the mechanisms behind it, we studied the effects of ERalpha signaling in ERalpha-transfected ERalpha-negative breast carcinoma cell lines, the MDA-MB-468 and the MDA-MB-231 and the effects of ERalpha knockdown in naturally expressing ERalpha-positive lines, MCF-7 and T47D. When ERalpha was overexpressed in the ERalpha-negative lines, 17beta-estradiol (E2) decreased slug and increased E-cadherin. Clones maximally exhibiting these changes grew more in clumps and became less invasive in Matrigel. When ERalpha was knocked down in the ERalpha-positive lines, slug increased, E-cadherin decreased, cells became spindly and exhibited increased Matrigel invasion. ERalpha signaling decreased slug expression by two different mechanisms: directly, by repression of slug transcription by the formation of a corepressor complex of ligand-activated ERalpha, HDAC inhibitor (HDAC1), and nuclear receptor corepressor (N-CoR) that bound the slug promoter in three half-site estrogen response elements (EREs); indirectly by phosphorylation and inactivation of GSK-3beta through phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt). The GSK-3beta inactivation, in turn, repressed slug expression and increased E-cadherin. In human breast cancer cases, there was a strong inverse correlation between slug and ERalpha and E-cadherin immunoreactivity. Our findings indicate that ERalpha signaling through slug regulates E-cadherin and EMT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101232     DOI: 10.1038/onc.2009.433

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  79 in total

Review 1.  Epigenetic regulation of epithelial-mesenchymal transition.

Authors:  Lidong Sun; Jia Fang
Journal:  Cell Mol Life Sci       Date:  2016-07-08       Impact factor: 9.261

2.  LEF1 targeting EMT in prostate cancer invasion is mediated by miR-181a.

Authors:  Jiaqian Liang; Xin Li; Yirong Li; Jianjun Wei; Garrett Daniels; Xuelin Zhong; Jinhua Wang; Karen Sfanos; Jonathan Melamed; Jun Zhao; Peng Lee
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 3.  The role of vitamin D in hepatic metastases from colorectal cancer.

Authors:  E Shaw; N Massaro; N T Brockton
Journal:  Clin Transl Oncol       Date:  2017-08-11       Impact factor: 3.405

4.  Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.

Authors:  Muralidharan Anbalagan; Mei Sheng; Brian Fleischer; Yifang Zhang; Yuanjun Gao; Van Hoang; Margarite Matossian; Hope E Burks; Matthew E Burow; Bridgette M Collins-Burow; David Hangauer; Brian G Rowan
Journal:  Mol Cancer Res       Date:  2017-07-27       Impact factor: 5.852

5.  Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma.

Authors:  Raheleh Roudi; Zahra Madjd; Marzieh Ebrahimi; Ali Najafi; Alireza Korourian; Ahmad Shariftabrizi; Ali Samadikuchaksaraei
Journal:  Tumour Biol       Date:  2016-04-05

6.  An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice.

Authors:  Mouad Edderkaoui; Chintan Chheda; Badr Soufi; Fouzia Zayou; Robert W Hu; V Krishnan Ramanujan; Xinlei Pan; Laszlo G Boros; Jian Tajbakhsh; Anisha Madhav; Neil A Bhowmick; Qiang Wang; Michael Lewis; Richard Tuli; Aida Habtezion; Ramachandran Murali; Stephen J Pandol
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

Review 7.  miR-221/222: promising biomarkers for breast cancer.

Authors:  Wei-Xian Chen; Qing Hu; Man-Tang Qiu; Shan-Liang Zhong; Jin-Jin Xu; Jin-Hai Tang; Jian-Hua Zhao
Journal:  Tumour Biol       Date:  2013-03-27

8.  The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines.

Authors:  Kristina Subik; Jin-Feng Lee; Laurie Baxter; Tamera Strzepek; Dawn Costello; Patti Crowley; Lianping Xing; Mien-Chie Hung; Thomas Bonfiglio; David G Hicks; Ping Tang
Journal:  Breast Cancer (Auckl)       Date:  2010-05-20

Review 9.  Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression.

Authors:  Ellen Foubert; Bram De Craene; Geert Berx
Journal:  Breast Cancer Res       Date:  2010-06-25       Impact factor: 6.466

10.  Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.

Authors:  Youn-Sang Jung; Su-Jin Lee; Min-Ho Yoon; Nam Chul Ha; Bum-Joon Park
Journal:  Cell Cycle       Date:  2012-11-16       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.